Adalimumab-induced acute myelogenic leukemia.
Newer biological treatment strategies have been developed in the last decade with some promising outcomes. Their safety, however, has been questioned lately with multiple reports of increased risk for malignancies and infectious complications. These reports render their use suboptimal. We report a 44-year-old woman receiving adalimumab (Humira) for advanced juvenile rheumatoid arthritis who then developed acute myelogenic leukemia.
Saba
Nakhle S
NS
Division of Hematology/Oncology, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, James H. Quillen VA Medical Center, TN 37684, USA.
Kosseifi
Semaan G
SG
Charaf
Edris A
EA
Hammad
Ahmad N
AN
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006400:Hematocrit; D006452:Hemoglobinometry; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000175:diagnosis; D007958:Leukocyte Count; D010976:Platelet Count
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab